Aspartate mutation distinguishes ETA but not ETB receptor subtype‐selective ligand binding while abolishing phospholipase C activation in both receptors
- 7 March 1995
- journal article
- research article
- Published by Wiley in FEBS Letters
- Vol. 361 (2-3) , 243-249
- https://doi.org/10.1016/0014-5793(95)00164-5
Abstract
The endothelin receptors, ETA and ETB, are G protein-coupled receptors (GPCR) that show distinctively different binding profiles for the endothelin peptides and other ligands. We recently reported that Tyr129 in the second transmembrane region (TM2) of the ETA receptor was critical for subtype-specific ligand binding [Krystek, S.R. et al. (1994) J. Biol. Chem. 269, 12383–12386]. Receptor models indicated that aspartic acids located one helical turn above (Asp133) and below (Asp126) Tyr129 in ETA had their side chains directed toward the putative binding cavity. Similarly in ETB, Asp147 and Asp154 are located one turn below and above His150, the residue that corresponds to Tyr129. Asp126 in ETA and Asp147 in ETB corresponds to the highly conserved aspartate present in TM2 of many GPCR that has frequently been shown to be crucial for agonist efficacy. Mutagenesis of Asp126 of the human ETA receptor to alanine resulted in an unaltered affinity for ET-1, a 160-fold increase in ET-3 affinity and a decrease in affinity for the ETA selective naphthalenesulfonamide, BMS-182874. ET-1 activation of phospholipase C was abolished. In addition, despite the gain in binding affinity, ET-3 failed to activate phospholipase C, suggesting that Asp126 is required for signal transduction. Mutagenesis of Asp133 to alanine indicated that it was critical only for the binding of BMS-182874. In the ETB receptor, mutation of His150 to alanine or tyrosine indicated that it plays a minor role in ETB subtype-selective ligand binding; mutation of the aspartates in TM2 of ETB did not alter ligand binding. As in the Asp126Ala ETA variant, ET-1 and ET-3 failed to increase intracellular levels of inositol phosphates in the Asp147Ala ETB mutant. Taken together, these data support the hypothesis that Asp126 and Asp133 flanking Tyr129 in TM2 of the ETA receptor play a role in defining ETA subtype-selective ligand binding but Asp147 and Asp154 that flank the His150 in TM2 of the ETB receptor do not. Furthermore, these data indicate that Asp126 in ETA and Asp147 in ETB are important for transmembrane signaling via phospholipase C.Keywords
This publication has 26 references indexed in Scilit:
- Characterization of human 5-HT1 receptors expressed in Sf9 insect cellsEuropean Journal of Pharmacology: Molecular Pharmacology, 1994
- The Discovery of Sulfonamide Endothelin Antagonists and the Development of the Orally Active ETA Antagonist 5-(Dimethylamino)-N-(3,4-dimethyl-5- isoxazolyl)-1-naphthalenesulfonamideJournal of Medicinal Chemistry, 1994
- Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonistNature, 1993
- A single amino acid of the cholecystokinin-B/gastrin receptor determines specificity for non-peptide antagonistsNature, 1993
- Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptorLife Sciences, 1992
- Identification of a domain of ETA receptor required for ligand bindingFEBS Letters, 1992
- Replacement of lysine‐181 by aspartic acid in the third transmembrane region of endothelin type B receptor reduces its affinity to endothelin peptides and sarafotoxin 6c without affecting G protein couplingJournal of Cellular Biochemistry, 1992
- Cloning and Expression of a Human Endothelin Receptor: Subtype AThe Lancet Healthy Longevity, 1992
- Sequence Alignment of the G-Protein Coupled Receptor SuperfamilyDNA and Cell Biology, 1992
- Model for the structure of bacteriorhodopsin based on high-resolution electron cryo-microscopyJournal of Molecular Biology, 1990